Press Releases
Amgen Wins Patent Case On Repatha
Amgen announced that a Delaware jury delivered a verdict in Amgen's favor in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). Amgen...
Press Releases
Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
Biocon Ltd. (BSE code: 532523, NSE: BIOCON) Asia's premier biopharmaceuticals company, announced today that its wholly owned subsidiary Biocon SA has entered into an agreement with Laboratorios PiSA S.A. de C.V (PiSA) of Mexico for the co-development and commercialization...
Press Releases
Scripps Florida Scientists Win $1.4 Million Grant to Develop New Ways to Block Breast Cancer
AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of...
Press Releases
ModiQuest Research and Sobi™ to Continue their Collaboration on Antibody Generation
The Dutch antibody services company, today announced that it will continue its collaboration with Sobi™ aimed at the generation of novel monoclonal antibodies against Sobi target(s). During the new project, ModiQuest will screen their high class...
Press Releases
ANI Pharmaceuticals and Dexcel Announce FDA Approval of Donepezil Hydrochloride 23mg Tablets
ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ: ANIP) today announced that its collaboration partner Dexcel Pharma Technologies Ltd. (“Dexcel”) has received approval from the U.S. Food and Drug Administration (“FDA”) of the Abbreviated New Drug Application (“ANDA”) for Donepezil HCl 23mg...
Press Releases
Abbott’s Absorb™, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Abbott announced that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks....
Press Releases
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors
Novartis announced that the United States FDA approved Afinitor® tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















